ADVANCED LUNG CANCER

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This study is testing two experimental drugs, BNT324 and BNT327, together in people with advanced lung cancer that has spread or come back. BNT324 targets and delivers a toxin to cancer cells, while BNT327 helps the immune system attack tumors and cuts off their blood supply. The…

This study tests a combination of four drugs (JS212, JS207, Toripalimab, and JS213) in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 864 participants will receive the drugs by …

This clinical trial is testing a new drug called TQB6411 in people with advanced lung cancer. The study has two phases: first to find the best dose, then to see how well it works. About 465 participants will receive the drug every 21 days. Researchers will measure tumor shrinkage…

This early-phase study tests a new cell therapy called GK01 in 10 people with advanced lung or esophageal cancer that no longer responds to standard treatments. The main goal is to check safety and how the body handles the therapy. Researchers will also look for early signs of tu…

This early-stage trial tests a new drug called HC010 combined with chemotherapy in people with advanced lung cancer that has spread or come back. The main goal is to find a safe dose and check for side effects. About 328 adults will take part, and researchers will also see if the…

This early-phase trial tests an inhaled mRNA vaccine called BMD006 in 83 people with advanced lung cancer or solid tumors that have spread to the lungs. The vaccine is designed to train the immune system to attack tumor-associated antigens. The study will check safety, tolerabili…

This study tests an experimental drug called MHB036C combined with other anti-cancer medicines in 300 people with advanced lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have tried standard treatments without success.

This study tests whether adding a hormone therapy (leuprorelin) to an immunotherapy (sintilimab) can help older men with advanced lung cancer. The idea is that lowering sex hormones may rejuvenate the immune system, making the immunotherapy more effective. Eighty men aged 60 and …

This study tests a mobile app called PROMOTE designed to help lung cancer survivors improve their physical function, manage shortness of breath and sleep problems, and adopt healthier habits. About 250 adults with early-stage lung cancer will either use the app for 12 weeks or re…

This study tests a telehealth program called ENGAGE for people with stage IV breast, prostate, lung, or colorectal cancer. The program helps manage symptoms like pain, fatigue, and distress that interfere with daily life. About 190 participants will be randomly assigned to ENGAGE…

This study tests whether a smartphone app that lets cancer patients report their symptoms, combined with regular calls from a specially trained nurse, can help them better manage chemotherapy side effects and improve their quality of life. The study includes 414 adults with early…